Baseline characteristics were balanced between the apixaban and warfarin cohorts. The mean age was 62 years with a mean CCI score of 2.9
| Warfarin cohort | Apixaban cohort | ||
|---|---|---|---|
| n (%) | n (%) | STD* | |
| Sample size | 12,340 | 7411 | |
| Age, mean (SD) | 62.1 (14.0) | 62.3 (13.9) | 1.81 |
| Gender | |||
| Male | 4511 (36.6) | 2702 (36.5) | 0.19 |
| Female | 7829 (63.4) | 4709 (63.5) | 0.19 |
| Index VTE setting | |||
| Inpatient | 8544 (69.2) | 5146 (69.4) | 0.44 |
| Outpatient | 3796 (30.8) | 2265 (30.6) | 0.44 |
| Index VTE event type | |||
| DVT only | 5294 (42.9) | 3183 (43.0) | 0.10 |
| PE with or without DVT | 7046 (57.1) | 4228 (57.0) | 0.10 |
| Deyo-Charlson Comorbidity Index, Mean (SD) | 2.9 (2.6) | 2.9 (2.6) | 0.45 |
